145 related articles for article (PubMed ID: 28161637)
1. Ameloblastin and enamelin prevent osteoclast formation by suppressing RANKL expression via MAPK signaling pathway.
Chaweewannakorn W; Ariyoshi W; Okinaga T; Morikawa K; Saeki K; Maki K; Nishihara T
Biochem Biophys Res Commun; 2017 Apr; 485(3):621-626. PubMed ID: 28161637
[TBL] [Abstract][Full Text] [Related]
2. Ameloblastin attenuates RANKL-mediated osteoclastogenesis by suppressing activation of nuclear factor of activated T-cell cytoplasmic 1 (NFATc1).
Chaweewannakorn W; Ariyoshi W; Okinaga T; Fujita Y; Maki K; Nishihara T
J Cell Physiol; 2019 Feb; 234(2):1745-1757. PubMed ID: 30105896
[TBL] [Abstract][Full Text] [Related]
3. Inhibitory effect and mechanism of 1,25-dihydroxy vitamin D3 on RANKL expression in fibroblast-like synoviocytes and osteoclast-like cell formation induced by IL-22 in rheumatoid arthritis.
Wen H; Liu Y; Li J; Wei D; Liu D; Zhao F
Clin Exp Rheumatol; 2018; 36(5):798-805. PubMed ID: 29465363
[TBL] [Abstract][Full Text] [Related]
4. Dominant negative N-cadherin inhibits osteoclast differentiation by interfering with beta-catenin regulation of RANKL, independent of cell-cell adhesion.
Shin CS; Her SJ; Kim JA; Kim DH; Kim SW; Kim SY; Kim HS; Park KH; Kim JG; Kitazawa R; Cheng SL; Civitelli R
J Bone Miner Res; 2005 Dec; 20(12):2200-12. PubMed ID: 16294273
[TBL] [Abstract][Full Text] [Related]
5. Ameloblastin modulates osteoclastogenesis through the integrin/ERK pathway.
Lu X; Ito Y; Atsawasuwan P; Dangaria S; Yan X; Wu T; Evans CA; Luan X
Bone; 2013 May; 54(1):157-168. PubMed ID: 23385480
[TBL] [Abstract][Full Text] [Related]
6. Nitrogen-containing bisphosphonate, YM529/ONO-5920 (a novel minodronic acid), inhibits RANKL expression in a cultured bone marrow stromal cell line ST2.
Nishida S; Tsubaki M; Hoshino M; Namimatsu A; Uji H; Yoshioka S; Tanimori Y; Yanae M; Iwaki M; Irimajiri K
Biochem Biophys Res Commun; 2005 Mar; 328(1):91-7. PubMed ID: 15670755
[TBL] [Abstract][Full Text] [Related]
7. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
[TBL] [Abstract][Full Text] [Related]
8. Deflazacort increases osteoclast formation in mouse bone marrow culture and the ratio of RANKL/OPG mRNA expression in marrow stromal cells.
Chung H; Kang YS; Hwang CS; Moon IK; Yim CH; Choi KH; Han KO; Jang HC; Yoon HK; Han IK
J Korean Med Sci; 2001 Dec; 16(6):769-73. PubMed ID: 11748360
[TBL] [Abstract][Full Text] [Related]
9. Accumulation of hyaluronic acid in stromal cells modulates osteoclast formation by regulation of receptor activator of nuclear factor kappa-B ligand expression.
Nakao Y; Hikiji H; Okinaga T; Takeuchi J; Habu M; Yoshiga D; Yoshioka I; Nishihara T; Ariyoshi W
Biochem Biophys Res Commun; 2019 May; 512(3):537-543. PubMed ID: 30914204
[TBL] [Abstract][Full Text] [Related]
10. Osteoblastic NF-κB pathway is involved in 1α, 25(OH)2D3-induced osteoclast-like cells formation in vitro.
Cong L; Zhang C; Tu G
Int J Clin Exp Pathol; 2015; 8(5):5988-96. PubMed ID: 26191332
[TBL] [Abstract][Full Text] [Related]
11. Pmepa1 induced by RANKL-p38 MAPK pathway has a novel role in osteoclastogenesis.
Funakubo N; Xu X; Kukita T; Nakamura S; Miyamoto H; Kukita A
J Cell Physiol; 2018 Apr; 233(4):3105-3118. PubMed ID: 28802000
[TBL] [Abstract][Full Text] [Related]
12. Human trabecular bone-derived osteoblasts support human osteoclast formation in vitro in a defined, serum-free medium.
Atkins GJ; Kostakis P; Welldon KJ; Vincent C; Findlay DM; Zannettino AC
J Cell Physiol; 2005 Jun; 203(3):573-82. PubMed ID: 15573398
[TBL] [Abstract][Full Text] [Related]
13. High molecular weight hyaluronic acid regulates osteoclast formation by inhibiting receptor activator of NF-κB ligand through Rho kinase.
Ariyoshi W; Okinaga T; Knudson CB; Knudson W; Nishihara T
Osteoarthritis Cartilage; 2014 Jan; 22(1):111-20. PubMed ID: 24185105
[TBL] [Abstract][Full Text] [Related]
14. Dual effect of WIN-34B on osteogenesis and osteoclastogenesis in cytokine-induced mesenchymal stem cells and bone marrow cells.
Seo BK; Ryu HK; Park YC; Huh JE; Baek YH
J Ethnopharmacol; 2016 Dec; 193():227-236. PubMed ID: 27401292
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms involved in suppression of osteoclast supportive activity by transforming growth factor-β1 via the ubiquitin-proteasome system.
Inoue M; Nagai-Yoshioka Y; Yamasaki R; Kawamoto T; Nishihara T; Ariyoshi W
PLoS One; 2022; 17(2):e0262612. PubMed ID: 35196318
[TBL] [Abstract][Full Text] [Related]
16. Bone morphogenetic protein 2 enhances mouse osteoclast differentiation via increased levels of receptor activator of NF-κB ligand expression in osteoblasts.
Tachi K; Takami M; Zhao B; Mochizuki A; Yamada A; Miyamoto Y; Inoue T; Baba K; Kamijo R
Cell Tissue Res; 2010 Nov; 342(2):213-20. PubMed ID: 20941510
[TBL] [Abstract][Full Text] [Related]
17. CTRP3 acts as a negative regulator of osteoclastogenesis through AMPK-c-Fos-NFATc1 signaling in vitro and RANKL-induced calvarial bone destruction in vivo.
Kim JY; Min JY; Baek JM; Ahn SJ; Jun HY; Yoon KH; Choi MK; Lee MS; Oh J
Bone; 2015 Oct; 79():242-51. PubMed ID: 26103094
[TBL] [Abstract][Full Text] [Related]
18. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M
J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972
[TBL] [Abstract][Full Text] [Related]
19. Macrophage inflammatory protein-1alpha (MIP-1alpha) enhances a receptor activator of nuclear factor kappaB ligand (RANKL) expression in mouse bone marrow stromal cells and osteoblasts through MAPK and PI3K/Akt pathways.
Tsubaki M; Kato C; Manno M; Ogaki M; Satou T; Itoh T; Kusunoki T; Tanimori Y; Fujiwara K; Matsuoka H; Nishida S
Mol Cell Biochem; 2007 Oct; 304(1-2):53-60. PubMed ID: 17549607
[TBL] [Abstract][Full Text] [Related]
20. Neogambogic Acid Suppresses Receptor Activator of Nuclear Factor κB Ligand (RANKL)-Induced Osteoclastogenesis by Inhibiting the JNK and NF-κB Pathways in Mouse Bone Marrow-Derived Monocyte/Macrophages.
Jin G; Wang FF; Li T; Jia DD; Shen Y; Xu HC
Med Sci Monit; 2018 Apr; 24():2569-2577. PubMed ID: 29698379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
